Moving Faster, with Confidence: An Interview with Ulrike Bauer, Chief Business Officer at Ypsomed
How can pharma and biotech companies accelerate drug-device programmes without shifting risk or bottlenecks further downstream? In this interview, Ypsomed chief business officer Ulrike Bauer discusses how platform flexibility, device readiness and tailored support for different programme pathways can help customers move from development through to commercial scale.
